EICHOR
● Active Not Recruiting
Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
Condition: Locally Advanced Uterine Corpus Leiomyosarcoma · Metastatic Uterine Corpus Leiomyosarcoma · Stage III Uterine Corpus Leiomyosarcoma AJCC v8 · Sponsor: National Cancer Institute (NCI)
About this study
This phase II/III trial compares the effect of the combination treatment with olaparib and temozolomide to trabectedin or pazopanib (two of the most common chemotherapy drugs used as usual approach) in patients with uterine leiomyosarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) after initial chemotherapy has stopped working. The usual approach is defined as care most people get for advanced uterine leiomyosarcoma. Olaparib is a PARP inhibitor. PARP is a protein that helps repair damaged deoxyribonucleic acid (DNA). Blocking PARP may prevent tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Temozolomide is in a class of medications called alkylating agents. It works by slowing or stopping the growth of tumor cells in the body. The combination of olaparib and temozolomide may work better than the usual treatment in shrinking or stabilizing advanced uterine leiomyosarcoma after initial chemotherapy has stopped working.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (145)
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | — |
| Alaska Women's Cancer Care | Anchorage, Alaska, United States | — |
| Mayo Clinic Hospital in Arizona | Phoenix, Arizona, United States | — |
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | — |
| Epic Care-Dublin | Dublin, California, United States | — |
| Epic Care Partners in Cancer Care | Emeryville, California, United States | — |
| City of Hope at Irvine Lennar | Irvine, California, United States | — |
| Contra Costa Regional Medical Center | Martinez, California, United States | — |
| Epic Care Cyberknife Center | Walnut Creek, California, United States | — |
| UCHealth University of Colorado Hospital | Aurora, Colorado, United States | — |
| UCHealth Memorial Hospital Central | Colorado Springs, Colorado, United States | — |
| Memorial Hospital North | Colorado Springs, Colorado, United States | — |
+ 133 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05432791